WO2001085145A8 - A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal - Google Patents

A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal

Info

Publication number
WO2001085145A8
WO2001085145A8 PCT/IB2001/000681 IB0100681W WO0185145A8 WO 2001085145 A8 WO2001085145 A8 WO 2001085145A8 IB 0100681 W IB0100681 W IB 0100681W WO 0185145 A8 WO0185145 A8 WO 0185145A8
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
treatment
pharmaceutically acceptable
disease
cognitive dysfunction
Prior art date
Application number
PCT/IB2001/000681
Other languages
French (fr)
Other versions
WO2001085145A2 (en
WO2001085145A3 (en
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Brian Thomas O'neill
Steven Bradley Sands
Eric Jacob Watsky
Original Assignee
Pfizer Prod Inc
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Neill Brian Thomas O
Steven Bradley Sands
Eric Jacob Watsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Jotham Wadsworth Coe, Edmund Patrick Harrigan, Neill Brian Thomas O, Steven Bradley Sands, Eric Jacob Watsky filed Critical Pfizer Prod Inc
Priority to BR0110487-0A priority Critical patent/BR0110487A/en
Priority to AU2001248699A priority patent/AU2001248699A1/en
Priority to CA002409720A priority patent/CA2409720A1/en
Priority to EP01921733A priority patent/EP1280554A2/en
Priority to MXPA02011051A priority patent/MXPA02011051A/en
Priority to JP2001581799A priority patent/JP2003532670A/en
Publication of WO2001085145A2 publication Critical patent/WO2001085145A2/en
Publication of WO2001085145A8 publication Critical patent/WO2001085145A8/en
Publication of WO2001085145A3 publication Critical patent/WO2001085145A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS associated dementia and schizophrenia. The method of using these compositions is also disclosed.
PCT/IB2001/000681 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal WO2001085145A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0110487-0A BR0110487A (en) 2000-05-09 2001-04-24 Pharmaceutical composition and method of treatment of cognitive dysfunction diseases in a mammal
AU2001248699A AU2001248699A1 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal
CA002409720A CA2409720A1 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
EP01921733A EP1280554A2 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal
MXPA02011051A MXPA02011051A (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal.
JP2001581799A JP2003532670A (en) 2000-05-09 2001-04-24 Pharmaceutical compositions and methods for the treatment of cognitive impairment disorders in mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09
US60/202,799 2000-05-09

Publications (3)

Publication Number Publication Date
WO2001085145A2 WO2001085145A2 (en) 2001-11-15
WO2001085145A8 true WO2001085145A8 (en) 2001-12-13
WO2001085145A3 WO2001085145A3 (en) 2002-06-13

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000681 WO2001085145A2 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal

Country Status (16)

Country Link
US (2) US20010036949A1 (en)
EP (1) EP1280554A2 (en)
JP (1) JP2003532670A (en)
AR (1) AR028426A1 (en)
AU (1) AU2001248699A1 (en)
BR (1) BR0110487A (en)
CA (1) CA2409720A1 (en)
EC (1) ECSP014065A (en)
GT (1) GT200100075A (en)
MX (1) MXPA02011051A (en)
PA (1) PA8516701A1 (en)
PE (1) PE20011256A1 (en)
SV (1) SV2002000440A (en)
TN (1) TNSN01068A1 (en)
UY (1) UY26693A1 (en)
WO (1) WO2001085145A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2138177A1 (en) * 2000-03-03 2009-12-30 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
EP1383733B1 (en) * 2001-04-20 2008-03-05 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
MXPA04001153A (en) * 2001-08-31 2005-02-17 Neurochem Int Ltd Amidine derivatives for treating amyloidosis.
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
BRPI0415165A (en) 2003-10-01 2007-01-09 Adolor Corp spirocyclic heterocyclic compound, pharmaceutical composition, method to bind opioid receptors, methods to prevent or treat pain, gastrointestinal dysfunction, a urogenital tract disorder, an immunomodulatory disorder, an inflammatory disorder, a respiratory function disorder, anxiety, mood disorder, a stress-related disorder, sympathetic nervous system disorder, cough, and a motor disorder, method for treating traumatic injury to the central nervous system, methods for preventing or treating stroke, cardiac arrhythmia, glaucoma, and sexual dysfunction, methods for treating a condition selected from the group consisting of shock, cerebral edema, cerebral ischemia, cerebral deficit after cardiac surgery (bypass) and graft, systemic lupus erythematosus, hodgkin's disease, sjogren's disease, epilepsy, and rejection in organ transplants and skin grafts, and to treat substance dependence, method to improve organ and cell survival, and cardioprotection after myocardial infarction, methods to reduce the need for anesthesia, to produce or maintain an anesthetic state, radiolabeled derivative of a compound, isotopically labeled derivative of a compound, compound and method of diagnostic imaging
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
CA2566373A1 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
EP2063886A2 (en) 2006-09-12 2009-06-03 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
FR2931677B1 (en) * 2008-06-02 2010-08-20 Sanofi Aventis ASSOCIATION OF A PARTIAL NICOTINIC RECEPTOR AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR, COMPOSITION CONTAINING THE SAME AND USE THEREOF IN THE TREATMENT OF COGNITIVE DISORDERS
EA022007B1 (en) 2009-09-11 2015-10-30 Пробиодруг Аг Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20150031655A1 (en) * 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
WO2001085145A2 (en) 2001-11-15
BR0110487A (en) 2003-04-01
JP2003532670A (en) 2003-11-05
CA2409720A1 (en) 2001-11-15
GT200100075A (en) 2001-12-31
AU2001248699A1 (en) 2001-11-20
UY26693A1 (en) 2001-12-28
AR028426A1 (en) 2003-05-07
US20030130303A1 (en) 2003-07-10
EP1280554A2 (en) 2003-02-05
SV2002000440A (en) 2002-10-24
PE20011256A1 (en) 2001-12-29
US20010036949A1 (en) 2001-11-01
PA8516701A1 (en) 2002-09-17
MXPA02011051A (en) 2003-03-10
WO2001085145A3 (en) 2002-06-13
ECSP014065A (en) 2003-01-13
TNSN01068A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
WO2001085145A8 (en) A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
AP2002002465A0 (en) Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders.
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
WO2002066427A3 (en) (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
HUP0101543A2 (en) Pharmaceutical compositions for treating femal sexual dysfunction
HK1064921A1 (en) Sustained release formulations of oxymorphone
AU3753695A (en) Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
LU91751I2 (en) Asenapin and its pharmaceutically acceptable derivatives (SYCREST®)
ATE269846T1 (en) N-SUBSTITUTED AMINOTETRALINES AS NEUROPEPTIDE Y Y5 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF OBESITY AND OTHER DISEASES
CA2284732A1 (en) Analogs of cocaine
CA2354237A1 (en) A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd)
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO1999005103A3 (en) 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
MY122477A (en) Sertraline oral concentrate
EP0976404A3 (en) A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
HUP0101326A2 (en) Paroxetine compositions and process for their preparation
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
YU24603A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
DZ3051A1 (en) Polymorphic forms of crystalline azo-bicycloÄ2,2,2Ü-oct-3-ylamine citrate, process for their preparation and pharmaceutical compositions containing them.
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
ZA200604748B (en) Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001921733

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2409720

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011051

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001921733

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001921733

Country of ref document: EP